Strategic Acquisition ALung was acquired by LivaNova in May 2022 for $10 million with additional sales-based milestones, indicating potential cross-sell opportunities leveraging LivaNova's broader cardiovascular and neurovascular portfolio.

Funding Trajectory Historical financing activity shows strong investor interest, including a $36M Series C in 2017 and a $12M financing in 2016, suggesting credibility and potential willingness from financiers to back growth or milestones.

Clinical Impact Hemolung RAS enables ultra-protective ventilation and COPD-related care by removing CO2 extracorporeally, presenting a sales angle targeting high-acuity ICUs, respiratory failure programs, and weaning-focused centers.

Market Position Small company size (11-50 employees) with a niche medical device offering positions ALung as a potential partner for specialized manufacturing, clinical trials, or pilot programs within larger medtech ecosystems.

Revenue Signals Reported revenue range ($1M-$10M) alongside substantial past funding indicates a growth-stage product ready for clinical adoption partnerships, distribution deals, or co-development agreements with larger device manufacturers.